OCS Overview

Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.

Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is40.00 USD with a low forecast of 29.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Oculis Holding AG revenue for the last quarter amounts to -20.63M USD, increased 19.54

Oculis Holding AG. EPS for the last quarter amounts to -16343000.00 USD, increased 56.92

Oculis Holding AG (OCS) has 60 emplpoyees as of March 12 2026.

Today OCS has the market capitalization of 1.58B USD.